WuXi TIDES to Host Peptide Drug Innovation Forum on Strategies and Solutions for Differentiated Development
WuXi AppTec
New Drug R&D and Production Service Provider
IMO
AI Large Molecule Drug Designer
As GLP-1 and its related target peptide drugs capture global attention, the pipeline for innovative peptide drugs is growing rapidly. Forward-looking strategies and differentiated innovation will become the key to breaking through.
Facing topics of common concern in the industry, WuXi AppTec's oligonucleotide and peptide drug CRDMO platform, WuXi TIDES, willSeptember 23Host "MoreStrategies and Solutions for Peptide Drug Innovation Breakthrough"Thematic Forum, Gathering Industry Pioneer Enterprises and Technical Experts, Discussing Core Challenges in Differentiated Innovation of Peptide Drugs, Sharing Successful Experiences in Building Key Competitive Advantages.
Let us work together to accelerate the breakthrough process of innovative peptide drugs and bring health benefits to patients worldwide!
September 23rd, 13:00-20:00
Shanghai Pudong Shangri-La Hotel
(No. 33 Fucheng Road, Pudong New Area)
Beijing Hall, Second Floor, Pujiang Building
(Sorted by the initial letter of the guests' surnames)
Mr. Chunlai Cao
Federal Bio
General Manager
Professor Chen Haifeng
IMO
Co-Founder
Dr. Bo Dan
Profound Creation
Chief Executive Officer
Huaqiang XuPh.D.
Kescend
Founder, Chairman
Dr. Zang Xiaoyu
Founder of N1 Life,
Chief Executive Officer, Chairman
13:00 - 13:30
Check-in
13:30 - 13:35
Opening Remarks
Ms. Lu Yu
Senior Vice President of WuXi AppTec, WuXi TIDES Oligonucleotides and
Head of Peptide Division and Head of Business Operations
13:35 - 14:05
Introduction to Weight Loss Drugs Developed Based on Gastrointestinal Hormones
Mr. Chunlai Cao
General Manager of Federal Bio
14:05 - 14:35
AI-Based Peptide Molecular Design
Professor Chen Haifeng
Co-founder of IMO
14:35 - 15:05
Innovative Drug Design for Metabolic Weight Loss Based on First Principles
Dr. Huaqiang Xu
Founder and Chairman of Kescend
15:05 - 15:25
Tea Break
15:25 - 15:55
Development of Radiopharmaceuticals with Significant Differentiation
Dr. Bo Dan
CEO of Borui Chuanghe
15:55 - 16:15
Integrated Platform Accelerates the Advancement of Peptide Drugs into Clinical Trials
Mr. Guoyong Fang
Vice President of WuXi AppTec, WuXi TIDES Oligonucleotides and
Head of Peptide Drug Development Department
16:15 - 16:35
Development and Case Studies of Polypeptide Drug Formulations
Dr. Ying Zhu
Vice President of WuXi AppTec, Head of Late-Stage Formulation Development and Commercial Business, and Head of China Business Development
16:35 - 17:35
Roundtable Discussion
Opportunities and Challenges in the Differentiated Innovation of Peptide Drugs
? Dr. Haiying He
Vice President of WuXi AppTec, Head of Oligonucleotide and Peptide Drug Chemistry Department
Mr. Chunlai Cao
General Manager of Federal Bio
Professor Chen Haifeng
Co-founder of IMO
Dr. Huaqiang Xu
Founder and Chairman of Kaithink
Dr. Zang Xiaoyu
Founder, CEO, and Chairman of N1 Life
18:00 - 20:00
TIDES NIGHT Cocktail Party
“
”
Press and hold/Scan the QR code to sign up immediately
●
This event is free and open to the public, primarily targeting heads of biotech companies, pharmaceutical enterprises, universities, and research institutions, with limited seats available.
●
Tickets must be approved by WuXi TIDES to be obtained.
●
The event will adopt a real-name check-in system based on the review information.